Protocol Ledger

NCT06216301 · Phase III · RECRUITING

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Interventional Phase III clinical trial protocol NCT06216301 sponsored by NovoCure in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-31 Enrollment: 734 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06216301
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)734 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06216301
Protocol FieldVerified Registry Value
NCT IdentifierNCT06216301
Consolidated Lead SponsorNovoCure
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment734 participants (ESTIMATED)
Registered Start Date2024-07-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06216301
Hospital Research SiteLocationSite Profile
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
University of Kansas Cancer Center - NorthKansas City, MOOpen Hospital Dossier ->
University of Kansas Cancer Center - Lee's SummitLee's Summit, MOOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI